You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Optimized lactoferrin for treatment of intracerebral hemorrhage
SBC: Pharmareview Corporation Topic: NINDSDESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New heterocyclic inhibitors of filoviruses
SBC: MICROBIOTIX, INC. Topic: HDESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New small molecule inhibitors of arenaviruses
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel commensal polysaccharide treats multiple sclerosis through Treg modulation
SBC: SYMBIOTIX BIOTHERAPIES, INC. Topic: NIAIDAbstract Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults, affecting over 350,000 patients in the US and over 2.5 million patients worldwide. MS is a disease of high unmetmedical need, currently treatable with one of several approved drugs, all of which result in either immune modulation or significant immunosuppre ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
DNP Polarization Agents for Real-Time Metabolic Imaging and Clinical Diagnosis
SBC: DYNUPOL, INC. Topic: NCIProject Summary / Abstract Although standard MRI techniques provide valuable structural insight, a related technique known as magnetic resonance spectroscopy (MRS) adds powerful real-time metabolic information about the tissues under study. MRS provides early detection of disease, monitoring treatment efficacy, and, in the case of cancer, a dramatic reduction in unnecessary biopsies. However, bro ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Screening for Novel CBS Inhibitors for Cancer Therapy
SBC: CBS THERAPEUTICS, INC. Topic: NCIDESCRIPTION (provided by applicant): Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide (H2S) in colorectal cancer: selective upregulation of cystathionine-b-synthase (CBS) and the subsequent production of H2S in colonic cancer cells serves as a pro-survival factor by stimulating tumor cell bioenergetics, growth, proliferation, migratio ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
AutoRegister: A system for enhancing the accuracy of tumor change detection
SBC: CORTICOMETRICS LLC Topic: NCIDESCRIPTION (provided by applicant): This project proposes to build an integrated software-based system for enhancing the accuracy of tumor change detection. The intent of the system, called AutoRegister, which is to be deployed on a clinical magnetic resonance imaging (MRI) scanner platform, is to automate the alignment of a patient's brain scan with that of a prior scan, such that subseque ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Stabilization of Therapeutic Peptides by Non-Perturbative Chemical Modification
SBC: VERAQUEL TECHNOLOGIES, INC. Topic: NIDDKDESCRIPTION (provided by applicant): Type 2 diabetes is a particularly debilitating disease and is endemic for a large proportion of the world's population. The unmet challenges in disease management are the lack of long-term efficacy in reducing hyperglycemia and the inability to stop progression. Glucagon-like peptide-1 (GLP-1), a natural gut hormone, provides a platform for therapeutics to ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
High-Purity Peptide Libraries without Chromatographic Separation
SBC: VERAQUEL TECHNOLOGIES, INC. Topic: NIEHSDESCRIPTION (provided by applicant): The market for peptide and protein products is 30 billion annually and continues to grow. Automated solid phase peptide synthesis (SPPS) is a mainstay of modern medicinal research, and has been used on micromole up tometric ton industrial scale. Peptide drugs such as Exenatide, a GLP-1 analogue and a life-saver to many type-2 diabetes patients, and Fuzeon for ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health